Table 1.
Patient characteristics (N=74)
| Cases n, (%) | |
|---|---|
| Age (years) | |
| <40 | 7 (9.5) |
| ≥40 | 67 (90.5) |
| Pretreatment evaluation methodsa | |
| MRI | 26 (35.1) |
| PET–CT | 19 (25.7) |
| Pelvic examination under anesthesia | 14 (18.9) |
| Neoadjuvant treatment | |
| None | 19 (25.7) |
| Neoadjuvant chemotherapy | 42 (56.8) |
| Neoadjuvant radio/chemoradiaotherapy | 13 (17.6) |
| Tumor size (cm) | |
| ≤4 cm | 41 (55.4) |
| >4 cm | 33 (44.6) |
| Histological subtype | |
| Squamous cell carcinoma | 65 (87.8) |
| Adenocarcinoma | 9 (12.2) |
| Pathological PMI | |
| Positive | 21 (28.4) |
| Negative | 53 (71.6) |
| LVSI | |
| Positive | 27 (36.5) |
| Negative | 47 (63.5) |
| Pelvic lymph node metastasis | |
| Positive | 31 (41.9) |
| Negative | 43 (58.1) |
| Deep stromal infiltration | |
| Positive | 62 (83.8) |
| Negative | 12 (16.2) |
| Surgical margins | |
| Positive | 7 (9.5) |
| Negative | 67 (90.5) |
| Postoperative treatment | |
| None | 7 (9.5) |
| Chemotherapy | 12 (16.2) |
| Radio/chemoradiotherapy | 55 (74.3) |
Notes:
a
All patients were routinely evaluated by pelvic examination and ultrasound in our study. The evaluation methods listed here include other image modalities except the routinely used methods mentioned earlier.
Abbreviations: MRI, magnetic resonance imaging; PET–CT, positron emission tomography–computed tomography; PMI, parametrial involvement; LVSI, lymphovascular space invasion.